6-[(2,2-diphenylethyl)amino]-N-[2-(1-piperidinyl)ethyl]-9-(β-D-ribofuranosyl)-9H-purine-2-carboxamide | 313344-83-1

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 6-[(2,2-diphenylethyl)amino]-N-[2-(1-piperidinyl)ethyl]-9-(β-D-ribofuranosyl)-9H-purine-2-carboxamide
• 英文别名: UK-371,104；9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-N-[2-(1-piperidinyl)ethyl]-9H-purine-2-carboxamide；9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-6-((2,2-diphenylethyl)amino)-N-(2-(piperidin-1-yl)ethyl)-9H-purine-2-carboxamide；9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(2,2-diphenylethylamino)-N-(2-piperidin-1-ylethyl)purine-2-carboxamide
• CAS: 313344-83-1
• 化学式: C₃₂H₃₉N₇O₅
• 分子量: 601.706
• InChiKey: ZNUJAZSDJXSBIG-YVIFWTNJSA-N

物化性质

• 熔点：
  182 °C
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  44
• 可旋转键数：
  11
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  158
• 氢给体数：
  5
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1-(2-氨乙基)哌啶 在 三氟甲磺酸三甲基硅酯 、 水 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 水 、 异丙醇 为溶剂， 反应 10.25h， 生成 6-[(2,2-diphenylethyl)amino]-N-[2-(1-piperidinyl)ethyl]-9-(β-D-ribofuranosyl)-9H-purine-2-carboxamide
  参考文献：
  名称：

  Development of a Scaleable Process for the Synthesis of the A2a Agonist, UK-371,104

  摘要：

  The development and utilization of a scaleable process for the manufacture of the A2a agonist UK-371,104 (1) is described. Key steps in the synthesis include (i) a palladium-catalyzed cyanation reaction to prepare the nitrile 10, (ii) a telescoped conversion of the acid 11 to the glycosidation substrate 9, and (iii) the stereoselective coupling of 8 with 9 in a glycosidation reaction mediated by TMS triflate in 1,2-dimethoxyethane followed by conversion through to 1.

  DOI：

  10.1021/op700248t

文献信息

• Purine derivatives
  申请人：Mantell Simon J.

  公开号：US06900309B1

  公开（公告）日：2005-05-31

  The present invention relates to compounds of the formula and pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds as adenosine A2a receptor agonists.

  本发明涉及具有以下公式的化合物、以及它们的药用可接受盐和溶剂化物，还涉及制备这些化合物、在制备中使用的中间体、包含这些化合物的组合物以及作为腺苷A2a受体激动剂的用途。
• Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20030013675A1

  公开（公告）日：2003-01-16

  A combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (i) an adenosine A 2A receptor agonist; and (ii) an anti-cholinergic agent, preferably comprising a member selected from the group consisting of tiotropium and derivatives thereof; the combination being therapeutically effective in the treatment of the diseases when administered by inhalation; as well as to a method of treating the obstructive airways and other inflammatory diseases comprising administering separately, simultaneously or sequentially to the mammal by inhalation a therapeutically effective amount of the combination of therapeutic agents; as well as to a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with the combination of therapeutic agents; as well as to a product containing the compounds of the combination for separate, simultaneous or sequential administration by inhalation to a mammal for the treatment of obstructive airways and other inflammatory diseases. It is preferred that the anti-cholinergic agent component be tiotropium bromide.

  一种用于治疗阻塞性气道和其他炎症性疾病的治疗剂组合，包括(i) 一种腺苷 A 2A 受体激动剂；以及(ii) 抗胆碱能药物，优选包含选自由噻托溴铵及其衍生物组成的组中的成员；当通过吸入给药时，该组合对治疗疾病有效；以及治疗阻塞性气道和其他炎症性疾病的方法，包括通过吸入给哺乳动物分别、同时或依次给药治疗有效量的治疗剂组合；以及包含药学上可接受的载体和治疗剂组合物的药物组合物；以及包含组合物化合物的产品，用于通过吸入对哺乳动物单独、同时或连续给药，以治疗阻塞性气道和其他炎症性疾病。抗胆碱能药物成分最好是噻托溴铵。
• Use of compounds in a dry powder inhaler
  申请人：——

  公开号：US20030064034A1

  公开（公告）日：2003-04-03

  The present invention relates to an inhaled formulation comprising a compound selected from a particular class of 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridines which is capable of delivering the compound as fine, solid particles to the lung and the use of such a formulation in the treatment of certain diseases such as respiratory diseases. By the use of such formulations, it is possible to eliminate the unwanted cough response associated with the use of these compounds in solution metered dose inhalers, which response can prevent the administration of a therapeutically effective dose and, in the long term, undermine patient compliance.

  本发明涉及一种吸入制剂，该制剂包含选自5,6-二氢-9H-吡唑并[lsqb;3,4-c]并[rsqb;-1,2,4-三唑并[lsqb;4,3-a]并[rsqb;吡啶]特定类别的化合物，该化合物能够以细小的固体颗粒形式输送到肺部，以及将这种制剂用于治疗某些疾病，如呼吸系统疾病。通过使用这种制剂，可以消除与在溶液计量吸入器中使用这些化合物有关的不希望出现的咳嗽反应，这种反应会妨碍给药治疗有效剂量，而且从长远来看，会影响患者的依从性。
• Pharmaceutical combination
  申请人：——

  公开号：US20030109485A1

  公开（公告）日：2003-06-12

  The present invention relates to a combination comprising (a) an adenosine A 2a receptor agonist as defined herein and (b) an adrenergic &bgr;2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.

  本发明涉及一种组合物，包括 (a) 腺苷 A 2a 受体激动剂和(b)肾上腺素能&bgr;2 受体激动剂的复方制剂，用于通过吸入途径同时、连续或单独给药，治疗阻塞性气道或其他炎症性疾病。
• Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
  申请人：——

  公开号：US20040171576A1

  公开（公告）日：2004-09-02

  The present invention relates to a combination of a selective adenosine A 2a receptor agonist and an anticholinergic agent for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease, with the proviso that the anticholinergic agent is not a tiotropium salt.

  本发明涉及一种选择性腺苷 A 2a 受体激动剂和抗胆碱能药物的组合，用于同时、连续或单独通过吸入途径给药，治疗阻塞性气道或其他炎症性疾病，但抗胆碱能药物不是噻托溴铵盐。